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Abstract
Background:	The	Caribbean	vervet	monkey	(Chlorocebus aethiops sabaeus)	is	a	poten-
tially	valuable	animal	model	of	neurodegenerative	disease.	However,	the	trajectory	of	
aging in vervets and its relationship to human disease is incompletely understood.
Methods:	To	characterize	biomarkers	associated	with	neurodegeneration,	we	meas-
ured	cerebrospinal	fluid	(CSF)	concentrations	of	Aβ1–40,	Aβ1–42,	total	tau,	and	p-	tau181 
in	329	members	of	a	multigenerational	pedigree.	Linkage	and	genome-	wide	associa-
tion were used to elucidate a genetic contribution to these traits.
Results:	Aβ1–40 concentrations were significantly correlated with age, brain total sur-
face	area,	and	gray	matter	thickness.	Levels	of	p-	tau181 were associated with cerebral 
volume	and	brain	total	surface	area.	Among	the	measured	analytes,	only	CSF	Aβ1–40 
was	heritable.	No	significant	linkage	(LOD	>	3.3)	was	found,	though	suggestive	linkage	
was	 highlighted	 on	 chromosomes	 4	 and	 12.	 Genome-	wide	 association	 identified	 a	 
suggestive	locus	near	the	chromosome	4	linkage	peak.
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1  | INTRODUCTION
Nonhuman	 primates,	 unlike	most	 other	model	 organisms	 (e.g.	 mice	
and	 rats),	 are	 known	 to	 develop	 age-	related	 amyloid	 pathology	
similar	 to	 that	 of	Alzheimer’s	 disease	 (AD)	 in	 humans	 (Kalinin	 et	al.,	
2013;	Ndung’u	 et	al.,	 2012;	 Podlisny,	Tolan,	 &	 Selkoe,	 1991;	 Rosen	
et	al.,	 2008;	 Toledano,	 Álvarez,	 López-	Rodríguez,	 Toledano-	Díaz,	 &	
Fernández-	Verdecia,	2014),	and	have	complex	behavioral	phenotypes	
closer	to	that	in	humans	than	other	species	could	achieve.	AD-	related	
genes, such as those encoding β-	amyloid	 (Aβ, APP)	 and	 tau	 (MAPT),	
are	 also	 highly	 similar	 (Holzer,	 Craxton,	 Jakes,	 Arendt,	 &	 Goedert,	
2004;	Podlisny	et	al.,	1991).	Tau	pathology,	though	reported	in	great	
apes, baboons, and lesser primates, appears far less abundant than 
in human disease, and distribution of amyloid pathology differs from 
that	in	human	AD	(Heuer,	Rosen,	Cintron,	&	Walker,	2012;	Toledano	
et	al.,	2014).	Correlation	of	amyloid	pathology	with	cognition	and	atro-
phy has been observed, but to a lesser degree compared with humans 
(Heuer	et	al.,	2012;	Toledano	et	al.,	2014).
The	 Caribbean	 vervet	 monkey	 (Chlorocebus aethiops sabaeus, 
also	known	as	 the	African	green	monkey),	 an	Old	World	monkey,	 is	
well-	suited	as	a	model	of	aging	and	neurodegenerative	disease;	com-
pared	to	rhesus	macaques,	vervets	are	more	available	and	carry	fewer	
pathogens.	Vervets	display	AD-	like	pathology,	including	accumulation	
of	Aβ-	containing	cerebral	plaques	associated	with	reactive	astrocyto-
sis,	dystrophic	neurites,	and	vascular	Aβ immunoreactivity resembling 
cerebral	amyloid	angiopathy	(CAA),	but	unlike	humans	have	relatively	
preserved	cognition	that	does	not	appear	correlated	with	plaque	bur-
den	 and	 demonstrate	 scant	 phosphorylated	 tau	 aggregates	 (Heuer	
et	al.,	2012;	Kalinin	et	al.,	2013;	Lemere	et	al.,	2004;	Toledano	et	al.,	
2014).	The	high	 incidence	of	Aβ	 immunoreactive	plaques	 in	vervets	
older	 than	 20	years	 of	 age	 (Kalinin	 et	al.,	 2013)	 suggests	 that	 they	
occur as part of the normal aging of the vervet.
In	humans,	cerebrospinal	fluid	(CSF)	harbors	useful	biomarkers	of	
neurodegenerative	disease.	CSF	levels	of	Aβ	and	tau	change	with	AD.	
Aβ exists in several isoforms, predominantly composed of residues 
1–40	 (Aβ1–40)	 and	 residues	 1–42	 (Aβ1–42).	Aβ1–40 is the most abun-
dant	isoform,	but	CSF	concentration	differences	of	Aβ1–40 are gener-
ally	subtle	in	AD	(Fagan	et	al.,	2007,	2014).	Indeed,	the	shorter	Aβ1–40 
isoform	is	more	predominant	in	CAA,	and	a	decrease	in	CSF	Aβ1–40 is 
associated	with	CAA	 (Verbeek	et	al.,	2009).	Aβ1–42 is less abundant, 
but	constitutes	 the	major	 isoform	present	 in	neuritic	plaques	 in	hu-
mans	 and	 in	vervets	 and	 is	more	 fibrillogenic.	 CSF	Aβ1–42 has been 
consistently	 shown	 to	 be	 decreased	 in	AD	 (Andreasen	 et	al.,	 1999;	
Fagan	et	al.,	2014;	Motter	et	al.,	1995;	Sunderland	et	al.,	2003;	Tapiola	
et	al.,	2009).	Some	authors	have	reported	that	the	Aβ1–42/Aβ1–40 ratio 
is	 a	 more	 accurate	 biomarker	 of	 AD	 than	Aβ1–42	 alone	 (Dumurgier	
et	al.,	 2015;	Hansson	 et	al.,	 2007;	 Lewczuk,	 Lelental,	 Spitzer,	Maler,	
&	Kornhuber,	2015;	Wiltfang	et	al.,	 2007).	CSF	 tau	and	phosphory-
lated	tau,	particularly	at	Threonine	181,	are	increased	in	AD	patients	
(Andreasen	 et	al.,	 1999;	 Fagan	 et	al.,	 2014;	 Sunderland	 et	al.,	 2003;	
Tapiola	et	al.,	2009;	Vandermeeren	et	al.,	1993),	however	the	mech-
anism	of	 tau	 egress	 into	 the	CSF	 and	 the	 relation	 to	 tau	pathology	
is	 unclear.	These	 CSF	 biomarkers	 have	 also	 been	 shown	 to	 change	
longitudinally	in	patients	with	familial	forms	of	AD	and	predict	clinical	
disease	progression	(Bateman	et	al.,	2012;	Fagan	et	al.,	2007;	Hansson	
et	al.,	2006).	Collection	of	CSF	enables	the	study	of	amyloid	pathology	
across a large sample of vervets and is a first step toward understand-
ing	the	translatability	of	CSF	biomarkers	between	human	and	vervet.
The	Vervet	Research	Colony	(VRC)	was	established	from	vervets	
captured	in	St.	Kitts	and	Nevis,	and	maintained	as	a	single	extended	
pedigree	(Jasinska	et	al.,	2012),	thereby	providing	a	large	sample	ideal	
for	mapping	 quantitative	 traits	 and	 study	 of	 complex	 neurobiologic	
traits.	Additionally,	the	wide	distribution	of	subjects	with	ages	across	
the	normal	vervet	 lifespan	enables	the	study	of	age-related	disease;	
vervets typically live to 11–13 years in the wild, but up to 25 years 
in	captivity	(Magden,	Mansfield,	Simmons,	&	Abee,	2015);	the	oldest	
animal	in	the	VRC	was	a	female	that	recently	died	at	29.1	years	of	age.	
Previous	work	in	the	VRC	reported	on	the	acquisition	and	analysis	of	
neuroanatomic	phenotypes	using	high-	resolution	structural	MRI	in	a	
large	number	of	colony	members	(Fears	et	al.,	2009,	2011).	In	the	cur-
rent	study,	we	extend	the	neurobiologic	characterization	of	the	VRC	
through	the	acquisition	and	analysis	of	CSF	biomarkers	in	the	context	
of the rich genetic and phenotypic information available through the 
VRC.
2  | METHODS AND MATERIALS
2.1 | Vervet pedigree
This	investigation	was	conducted	as	approved	by	the	Animal	Research	
Committee	 in	 the	 Office	 for	 Protection	 of	 Research	 Subjects	 at	
UCLA	and	the	Institutional	Animal	Care	and	Use	Committees	at	the	
Sepulveda	 Veterans	 Administration	 Medical	 Center	 and	 the	 Wake	
Forest	School	of	Medicine.	The	vervet	subjects	analyzed	in	this	study	
are part of a pedigree that has included more than 1,000 animals since 
its	founding.	The	VRC	was	established	during	the	1970s	and	1980s	
Conclusions:	Overall,	these	results	support	the	vervet	as	a	non-	human	primate	model	
of	amyloid-	related	neurodegeneration,	such	as	Alzheimer’s	disease	and	cerebral	amy-
loid	angiopathy,	and	highlight	Aβ1–40	and	p-	tau181	as	potentially	valuable	biomarkers	of	
these processes.
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from 58 founder animals that were captured from a wild population 
in	the	islands	of	St.	Kitts	and	Nevis.	Vervet	monkeys	originally	arrived	
in	 the	Caribbean	 Islands	 in	 the	 1600s	 on	 trading	 ships	 from	Africa	
(McGuire,	1974).	Since	the	founding	of	the	colony,	breeding	has	been	
managed	to	provide	a	species-	typical	social	environment	for	develop-
ing offspring and to promote genetic diversity, while preserving each 
of	the	original	matrilines	to	simulate	the	social	structure	of	wild-	living	
troops.	Female	offspring	remain	in	the	breeding	groups,	and	males	are	
removed to separate housing at 4 years of age as previously described 
(Fairbanks	et	al.,	2004).	Adult	males	born	in	different	social	groups	are	
introduced into the breeding groups at 3–4 year intervals; because 
no new animals have been imported for several decades, extensive 
inbreeding	 occurs.	 The	 average	 inbreeding	 coefficient	 (probability	
that	a	subject	receives	two	alleles	identical-	by-	descent)	in	the	colony	
was	recently	characterized	at	0.006,	with	animals	with	non-	zero	 in-
breeding	coefficient	ranging	from	0.004	to	0.25	(mean	0.05;	Freimer	
et	al.,	2007).	The	high	level	of	inbreeding	facilitates	genetic	mapping	
in	our	study	population,	 improving	 the	effective	sample	size	 for	as-
sociation	and	providing	a	high	 informative	pedigree	for	 linkage.	The	
genetic architecture and genetic control of traits may not reflect out-
bred populations.
Vervets were fed commercial laboratory chow ad lib, supple-
mented by fresh fruits and produce. Specifically, the vervet chow has 
primarily	been	LabDiet	5038	(“Monkey	Diet”),	with	several	exceptions.	
During	2004	to	2008,	animals	were	fed	LabDiet	5052	(“Fiber-	Balanced	
Monkey	Diet”)	as	previously	described	(Fairbanks,	Blau,	&	Jorgensen,	
2010).	 For	 6	months	 in	 mid	 2009,	 animals	 were	 fed	 LabDiet	 5L0P	
(“Typical	American	Primate	Diet”)	as	previously	described	 (Voruganti	
et	al.,	2013).
2.2 | CSF biomarker measurements
CSF	 was	 collected	 from	 the	 cisterna	 magna	 of	 each	 animal	 under	
a	 protocol	 approved	 by	 the	 Animal	 Research	 Committee	 at	 the	
University	of	California,	Los	Angeles,	as	previously	described	(Freimer	
et	al.,	2007).	CSF	protein	concentrations	were	measured	at	the	Knight	
Alzheimer’s	 Disease	 Research	 Center	 (ADRC)	 Biomarker	 Core	 Lab	
at	Washington	University	 in	St.	Louis	as	previously	described	(Shaw	
et	al.,	 2011).	 Concentrations	 of	 CSF	 Aβ1–40 were measured with 
the	 INNOTEST	 β-	AMYLOID(1–40)	 solid-	phase	 enzyme	 immunoassay	
(Innogenetics	N.V.,	Ghent,	Belgium).	Briefly,	the	amyloid	peptides	are	
first	captured	by	the	2G3	monoclonal	antibody,	and	quantified	with	a	
biotinylated monoclonal antibody, 3D6. The protein is then detected 
using	 a	 peroxidase-	labeled	 streptavidin	 readout.	 Concentrations	 of	
CSF	 Aβ1–42,	 tau,	 and	 phosphorylated	 tau	 (p-	tau181)	 were	measured	
simultaneously	 with	 the	 INNO-	BIA	 AlzBio3	 fluorimetric	 immuno-
assay	 (Innogenetics	 N.V.,	 Gent,	 Belgium).	 Briefly,	 the	 proteins	 are	
first	captured	on	beads	by	specific	monoclonal	antibodies	–	4D7A3	
for	Aβ1–42,	AT120	for	 tau,	and	AT270	for	p-	tau181.	Additional	bioti-
nylated	antibodies	are	then	used	to	quantify	the	proteins	–	3D6	for	
Aβ1–42,	and	HT7	for	tau	and	p-	tau181. The proteins are then detected 
using	a	phycoerythrin-	labeled	streptavidin	readout.	Calibration	of	the	
standard	 curve	 was	 performed	 as	 described	 in	 the	 manufacturer’s	
directions	using	 six	accompanying	 standards	provided	 in	 the	kit.	All	
assays	were	run	in	duplicate.	Measurements	with	coefficient	of	vari-
ation	(CV)	>25%	or	bead	count	<30	were	excluded	in	quality	control.
2.3 | Neuroimaging analysis
Neuroimaging	data	were	acquired	 in	2007;	details	of	 the	 image	ac-
quisition	and	pre-	processing	protocol	have	been	described	previously	
(Fears	 et	al.,	 2009).	 To	 generate	 high	 signal-	to-	noise	 images,	 nine	
separate	 structural	 scans	were	 acquired	 from	357	 animals	 (256	 fe-
males	and	101	males)	using	an	8-	channel	high-	resolution	knee	array	
coil	 as	 a	 receiver	 in	 a	 1.5	 Tesla	 Siemens	 (Erlanger)	 Symphony	 unit.	
The	 images	were	acquired	as	axial	T1-	weighted	volumes	with	a	3D	
magnetization	 prepared	 rapid	 acquisition	 gradient	 echo	 (MPRAGE);	
TR = 1,900 msec, TE = 4.38 msec, TI = 1,100 msec, flip angle = 15 
degrees, and voxel resolution = 0.5 mm in all three planes. The nine 
separate	 images	were	 aligned	 to	 each	other	 in	 pair-	wise	 rigid	body	
registrations and averaged together prior to segmentation. The age at 
CSF	biomarker	collection	and	measurement	(performed	in	2012)	was	
approximately	5	years	 following	 the	 age	 at	MRI	measurement	 (per-
formed	in	2007);	analyses	were	performed	with	each	animal	from	the	
CSF	analysis	paired	with	their	own	earlier	scan	data.
Details of the six brain phenotypes investigated in the initial as-
sociation	analysis	have	been	described	previously	(Fears	et	al.,	2009).	
For	the	secondary	analysis	of	regional	cortical	phenotypes,	the	images	
were	segmented	to	generate	cortical	thickness	and	surface	area	mea-
sures using a combination of manual and automated methods. Thirty 
images were manually segmented into 29 regions based on each sub-
ject’s	 anatomical	 details.	 The	 30	 manually	 segmented	 images	 were	
used	as	input	for	the	Freesurfer	(RRID:SCR_001847)	program	‘mri_ca_
train’	 to	 generate	 a	 probabilistic	 anatomical	map	 (https://surfer.nmr.
mgh.harvard.edu/fswiki/mri_ca_train)	that	was	then	used	to	segment	
the	 entire	 dataset.	The	 Freesurfer	 segmented	 images	were	 then	 in-
spected and manually adjusted to correct gross segmentation errors.
2.4 | Statistical analysis
Brain-	CSF	 associations	 were	 tested	 using	 linear	 regression	 as	
implemented	 with	 the	 Sequential	 Oligogenic	 Linkage	 Analysis	
Routines	 (SOLAR)	 software	 package	 (Almasy	 &	 Blangero,	 1998;	
RRID:SCR_000850).	SOLAR	uses	the	pedigree	structure	to	adjust	for	
the dependency structure among the subjects that would otherwise 
violate	assumptions	for	standard	 linear	 regression	methods.	For	 the	
neuroimaging measures, age and sex were controlled as covariates in 
a	linear	regression	model;	the	residuals	were	then	associated	with	CSF	
traits.	The	procedure	of	Benjamini	and	Hochberg	was	used	to	correct	
for multiple testing to identify significant associations in the initial set 
of	six	neuroimaging	traits	with	the	four	CSF	traits	(24	tests),	using	a	
false	discovery	rate	(FDR)	threshold	of	0.05.	In	the	secondary	analy-
sis	of	 regional	 cortical	measures	of	 thickness	and	 surface	area	with	
Aβ1–40	and	p-	tau181	traits,	the	procedure	of	Benjamini	and	Hochberg	
was similarly used, applied to each of the two sets of association tests 
independently	(29	tests	per	set).
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2.5 | Heritability calculations and linkage analysis
A	whole-	genome	sequencing	strategy	was	used	to	identify	and	type	
vervet	polymorphisms,	as	previously	described	 (Huang	et	al.,	2015).	
The	 vervet	 pedigree	 was	 visualized	 using	 the	 “kinship2”	 package.	
Heritability	analysis	was	performed	using	SOLAR.	The	variance	com-
ponent	models	of	SOLAR	assume	normality	in	the	trait	distributions;	
therefore,	 in	 order	 to	 force	 the	 distribution	of	CSF	biomarker	 phe-
notypes	to	approximately	normal	and	correct	for	skew	and	kurtosis,	
the	 inverse	 normal	 transformation	 was	 used.	 For	 each	 phenotype,	
the correlation to age and sex covariates was evaluated. Residuals 
after regression for significant covariates were used in downstream 
analyses. Quantitative polygenic screening was performed as previ-
ously	described	using	the	“polygenic”	function	of	SOLAR,	yielding	an	
estimate	of	the	narrow-	sense	polygenic	heritability	(h2, a measure of 
the	fraction	of	phenotypic	variance	due	to	additive	genetic	factors);	a	
p-	value	for	this	estimate;	and	the	proportion	of	variance	attributable	
to	covariates.	Genetic	mapping	was	performed	using	multipoint	link-
age	analysis	implemented	in	SOLAR.	First,	the	multipoint	identity-	by-	
descent	(IBD)	relationships	were	computed	for	the	vervet	pedigree	as	
previously	described	 (Huang	et	al.,	 2015).	A	multipoint	 linkage	 scan	
was then run with an interval of 5 centimorgans. LOD scores were 
considered suggestive at a threshold of 1.9, and significant at a thresh-
old	of	3.3	as	previously	proposed	(Lander	&	Kruglyak,	1995).	Zero-	in	
scans	at	finer	scales	were	performed	at	peaks	with	LOD	scores	>2.	The	
confidence	region	around	a	peak	was	defined	as	the	region	spanned	
by	1	LOD	intervals	to	either	side	of	the	peak.
2.6 | Association testing
The	 EMMAX	 software	 was	 used	 to	 map	 genetic	 associations	
with	 CSF	 biomarker	 phenotypes	 in	 the	 vervet	 (Kang	 et	al.,	 2010;	
RRID:SCR_008217).	EMMAX	uses	a	variance	component	model	to	
account	for	high	relatedness	among	the	vervet	subjects	(estimated	
from	pairwise	kinship	calculated	by	identity-	by-	state).	A	linear	mixed	
model was then fit to the data and used to calculate the association. 
We	 used	 standard	 genome-	wide	 significant	 thresholds	 from	 hu-
mans	(significant	at	p	<	5	×	10−8, suggestive at p	<	5	×	10−6;	Risch	&	
Merikangas,	1996),	which	should	approximate	appropriate	values	in	
vervet given the relatively recent divergence between apes and Old 
World	Monkeys	(approximately	25	million	years),	and	the	similarity	
in	genome	size	between	human	and	vervet	(Warren	et	al.,	2015).
3  | RESULTS
3.1 | Vervet subject characteristics
Animals	were	selected	from	a	complex,	nine-	generation-	deep	vervet	
pedigree	 with	 a	 high	 degree	 of	 consanguineous	 mating.	 Following	
quality	 control	 procedures	 (see	 Methods),	 CSF	 concentrations	 of	
Aβ1–40,	Aβ1–42,	tau,	and	p-	tau181	(tau	phosphorylated	at	Thr181)	were	
obtained	 in	a	total	of	329	animals	 (Table	1).	Unexpectedly,	 for	each	
demographic category, mean total tau concentrations were lower than 
those	of	p-	tau181.	The	distributions	of	CSF	concentrations	of	Aβ1–40, 
Aβ1–42,	tau,	and	p-	tau181	were	skewed	(Table	1,	Figure	S1).	Levels	of	
Aβ1–40	were	inversely	correlated	with	age	(r	=	−.17,	p	=	.00094),	while	
levels	of	Aβ1–42,	tau,	and	p-	tau181	were	not	(r	=	−.039,	.0086,	.07,	and	
p	=	.47,	.87,	and	.19,	respectively;	Figure	S2).	The	correlation	between	
age	and	CSF	Aβ1–40	was	consistent	when	excluding	animals	>10	years	
of	age	(r	=	−.13,	p	=	.093).
3.2 | Species differences and polymorphisms in the 
vervet β- amyloid and tau proteins
The	antibody-	based	CSF	assays	were	designed	and	validated	for	hu-
mans;	 therefore,	we	evaluated	whether	 species-	specific	 differences	
or polymorphisms in the vervet orthologs of APP	(encoding	the	amy-
loid	precursor	protein)	and	MAPT	(encoding	tau)	could	affect	the	per-
formance of the antibodies.
Species-	specific	differences	between	vervet	and	human	in	the	an-
tibody	epitope	regions	were	first	identified.	Across	the	Aβ peptide the 
human	and	vervet	proteins	were	identical,	including	the	2G3,	4D7A3,	
and	3D6	epitope	regions	(Figure	S3).	Differences	were	found	between	
the human tau protein and the vervet ortholog, including a single 
amino	acid	 substitution	 (threonine	 to	alanine)	 in	 the	AT120	epitope	
region, which could affect the results for total tau concentration.
Coding	polymorphisms	across	vervet	subjects	were	then	identified	
to	determine	whether	 inter-	individual	differences	in	the	polypeptide	
sequence	 of	 Aβ	 or	 tau	 could	 confound	 their	 quantification.	 In	 our	
cohort,	polymorphisms	were	identified	in	APP	(Ala15Ser)	and	MAPT	
N (%)
Ab40 mean 
(SD), pg/ml
Ab42 mean 
(SD), pg/ml
Tau mean 
(SD), pg/ml
pTau mean 
(SD), pg/ml
All 329	(100) 10267	(4250) 506	(166) 23	(6) 30	(11)
0–5 years old 87	(26) 11047	(3880) 505	(181) 23	(5) 30	(10)
5–10 years old 99	(30) 10282	(3819) 503	(169) 22	(6) 29	(12)
10–15 years old 78	(24) 10094	(4509) 499	(162) 23	(8) 28	(11)
15–20 years old 45	(14) 10289	(5332) 499	(168) 23	(8) 33	(11)
20+ years old 20	(6) 7416	(2939) 556	(92) 22	(4) 36	(14)
Male 55	(17) 11151	(4371) 529	(154) 21	(2) 33	(11)
Female 274	(83) 10088	(4211) 501	(168) 23	(7) 29	(11)
TABLE  1 Characteristics	of	vervet	
subjects used in the analysis, at the time of 
CSF	collection
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(Gly148Arg	and	Leu213Pro).	None	overlapped	with	the	antibody	epi-
tope regions; furthermore, no associations between these polymor-
phisms	and	quantified	CSF	concentrations	were	observed	(Figure	S4).
3.3 | Relation between CSF biomarker level and 
brain structure
Brain	imaging	phenotypes	and	genetic	data	had	been	collected	as	part	
of	a	previous	 study	 (Fears	et	al.,	2009).	 In	 total,	both	CSF	biomarker	
measurements and neuroimaging data were measured in 209 animals. In 
general, this subgroup had fewer animals of very young age, due to the 
time	interval	between	studies	(Figure	S5).	To	determine	the	relationship	
between	 the	CSF	concentrations	of	Aβ1–40,	Aβ1–42,	 tau,	 and	p-	tau181 
with neuroimaging phenotypes, we initially calculated the correlations 
of	 CSF	 biomarker	 concentrations	 with	 six	 global	 measures	 (cerebral	
volume,	cerebellar	volume,	hippocampal	volume,	cross-	sectional	area	
of	the	corpus	callosum,	total	gray	matter	thickness,	and	total	surface	
area;	see	Table	2	and	Figure	1),	after	correction	for	age	and	sex.	At	a	
nominal	 significance	 threshold	 (p	=	.05),	 Aβ1–40 was correlated with 
corpus	 callosum	 cross-	sectional	 area	 (p	=	.024),	 hippocampal	 volume	
(p	=	.013),	total	gray	matter	thickness	(p	=	.007),	and	total	surface	area	
(p	=	.006).	 The	 correlation	with	 total	 gray	matter	 thickness	 and	 total	
surface	area	was	significant	(controlling	FDR	at	0.05)	after	applying	the	
Benjamini-	Hochberg	correction	for	multiple	comparisons.	The	direction	
of each regression coefficient was positive; higher concentrations of 
Aβ1–40	were	associated	with	 larger	brain	size.	Likewise,	p-	tau181 con-
centrations	were	correlated	with	cerebral	volume	 (p	=	.001),	 cerebel-
lar	 volume	 (p	=	.039),	 corpus	 callosum	cross-	sectional	 area	 (p	=	.018),	
hippocampal	volume	 (p	=	.039),	and	 total	 surface	area	 (p	=	.008).	The	
correlation with cerebral volume and total surface area was significant 
after	the	Benjamini-	Hochberg	correction.	In	contrast	with	Aβ1–40, the 
sign of each regression coefficient was negative; that is, higher concen-
trations	of	p-	tau181	tended	to	be	associated	with	smaller	brain	sizes.
Because	 we	 observed	 suggestive	 association	 between	 Aβ1–40 
and	 p-	tau181 and multiple neuroimaging traits, we further tested 
for	associations	between	CSF	concentrations	of	Aβ1–40	and	p-	tau181 
and	 regional	measures	 of	 gray	matter	 thickness	 and	 surface	 area	
across	the	cortex	(Table	S1).	MRI	measurements	were	adjusted	for	
age and sex, and the residuals were used for downstream analyses. 
Hypothesis	 tests	 for	each	association	were	corrected	 for	multiple	
comparisons	using	 the	method	of	Benjamini	and	Hochberg,	yield-
ing	 adjusted	 p-	values	 (pBH)	 that	 control	 for	 the	 false	 discovery	
rate.	Concentrations	of	Aβ1–40 were correlated with increased gray 
matter	 thickness	 across	many	 brain	 regions,	 including	 the	 orbital	
frontal	gyri	(linear	regression	coefficient	β = 0.26, pBH	=	0.002),	lin-
gual	 gyrus	 (β = 0.19, pBH	=	0.040),	 inferior	 frontal	 gyrus	 (β = 0.17, 
pBH	=	0.040),	 precuneus	 (β = 0.18, pBH	=	0.040),	 angular	 gyrus	
(β = 0.17, pBH	=	0.040),	middle	frontal	gyrus	(β = 0.17, pBH	=	0.040),	
inferior	 precentral	 gyrus	 (β = 0.17, pBH	=	0.040),	 superior	 precen-
tral	 gyrus	 (β = 0.16, pBH	=	0.044),	 superior	 frontal	 gyrus	 (β = 0.16, 
pBH	=	0.044),	postcentral	gyrus	 (β = 0.16, pBH	=	0.044),	 and	 lateral	
occipital	gyri	(β = 0.16, pBH	=	0.047;	Table	S1,	Figure	2).	Significant	
correlations with surface area were limited to the lateral occipi-
tal	 gyrus	 (β = 0.20, PBH	=	0.027).	Concentrations	 of	 p-	tau181 were 
correlated	 with	 decreased	 gray	 matter	 thickness	 in	 the	 fusiform	
gyrus	(β	=	−0.20,	pBH	=	0.022),	and	surface	area	of	the	corpus	cal-
losum	(β	=	−0.22,	pBH	=	0.009)	and	inferior	occipital	gyri	(β	=	−0.17,	
pBH	=	0.049).	 The	 direction	 of	 relationship	was	 largely	 consistent	
with	those	in	the	global	brain	measures;	Aβ1–40 was generally cor-
related	with	increased	gray	matter	thickness	and	surface	area,	while	
p-	tau181	was	generally	correlated	with	decreased	gray	matter	thick-
ness and surface area of brain structures. Of these brain regions, 
only	 the	 gray	matter	 thickness	 in	 the	 fusiform	 gyrus	was	 signifi-
cantly correlated with age, after correction for multiple comparisons 
(uncorrected	p	=	3.68	×	10−14).	Fitting	a	linear	regression	model	for	
fusiform	gyrus	gray	matter	thickness	using	both	CSF	p-	tau181 and 
age	 at	MRI	 scan	 as	 covariates,	we	 found	 that	 both	 age	 (β = 0.20, 
p	=	1.03	×	10−6)	and	p-	tau181	(β = 0.20, p	=	.0015)	were	strong	pre-
dictors.	This	pattern	remained	even	after	including	age	at	CSF	draw	
(p	=	.00057	for	p-	tau181),	suggesting	that	the	contributions	of	CSF	
Aβ1–40	 and	 p-	tau181 on regional brain volume measurements that 
we have identified are independent of age.
3.4 | Heritability and genetic mapping of 
CSF biomarkers
We	first	sought	to	quantify	the	heritability	of	CSF	Aβ1–40,	Aβ1–42, tau, 
and	p-	tau181	concentrations.	Narrow-	sense	polygenic	heritability	(h
2)	
TABLE  2 Associations	of	global	measures	of	brain	size	with	CSF	biomarkers
Ab40 Ab42 tau p- tau
N β p N β p N β p N β p
Cerebral	volume 209 0.09 .09 200 −.007 .90 207 .004 .94 204 −.17 .001
Cerebellar	volume 209 0.03 .58 200 .002 .98 207 −.03 .53 204 −.11 .039
Corpus	callossum	cross	
sectional area
209 0.12 .024 200 −.07 .22 207 .006 .91 204 −.12 .018
Hippocampal	volume 209 0.14 .013 200 −.03 .58 207 −.03 .58 204 −.12 .039
Total gray matter 
thickness
206 0.17 .007 197 .05 .50 204 −.07 .26 201 −.13 .05
Total surface area 206 0.14 .006 197 −.005 .93 204 .005 .93 201 −.14 .008
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was	estimated	using	SOLAR,	taking	into	account	age	and	sex	as	pos-
sible	covariates.	After	correcting	for	relatedness,	CSF	Aβ1–40	(p	=	.001)	
and	p-	tau181	 (p	=	.01)	were	significantly	correlated	with	age,	but	not	
Aβ1–42	(p	=	.46)	or	tau	(p	=	.31).	CSF	p-	tau181	(p	=	.007)	but	not	Aβ1–40 
(p	=	.32),	Aβ1–42	 (p	=	.25),	or	tau	(p	=	.14)	was	significantly	correlated	
with	 sex.	The	CSF	concentration	of	Aβ1–40 was found to be signifi-
cantly	heritable	(h2 = 0.22, p	=	.01).	CSF	concentrations	of	Aβ1–42, tau, 
and	p-	tau181	were	not	heritable	(h
2 = 0.05, p = .35; h2 = 0.07, p = .15; 
and h2 = 0, p	=	.50,	respectively).
Because	of	the	demonstrated	heritability	of	CSF	Aβ1–40 concentra-
tion, we then attempted to map genetic loci that could play a role in 
the	phenotypic	variation	using	genome-	wide	multipoint	linkage	anal-
ysis.	At	a	LOD	score	 threshold	of	3.3,	no	markers	 reached	genome-	
wide	significance	(Figure	S6).	Two	peaks	were	suggestive	for	linkage	
(LOD	>	1.9),	 including	 a	 9	cM	 region	 on	 vervet	 chromosome	 4,	 be-
tween	67	Mb	and	74	Mb	 (maximum	LOD	of	2.5)	and	a	6	cM	region	
on	 vervet	 chromosome	 12,	 between	 30	Mb	 and	 37	Mb	 (maximum	
LOD	of	2.2).	We	additionally	performed	association	as	a	complemen-
tary mapping approach, correcting for family structure using a linear 
mixed	 model	 approach	 implemented	 using	 the	 EMMAX	 software	
(Kang	 et	al.,	 2010).	 No	 markers	 reached	 genome-	wide	 significance,	
but a suggestive association was identified on chromosome 4 near the 
proximal	end	of	the	linkage	peak	(minimum	p	=	5.68	×	10−8	at	marker	
CAE4_67028748,	Figure	S7).	Genes	within	500,000	base	pairs	of	this	
marker	 included	MAP1B, MRPS27, PTCD2, ZNF366, TNPO1, FCHO2, 
TMEM171, and TMEM174.
4  | DISCUSSION
We	report	the	measurement	of	CSF	biomarkers	in	a	colony	of	vervet	
monkeys,	a	potentially	valuable	nonhuman	primate	model	for	neuro-
degenerative	 diseases.	 This	 dataset	 spans	 vervet	monkeys	 of	 vary-
ing	age,	 from	1	year	of	age	to	27	years	of	age.	For	context,	vervets	
typically live to 11–13 years of age in the wild, and about 25 years in 
captivity	(Magden	et	al.,	2015).	As	AD	and	other	neurodegenerative	
diseases	are	highly	age-	related	in	humans,	the	study	of	this	large	data-
set is ideal for dissecting the applicability of vervets in human disease.
AD	in	humans	is	thought	to	result	in	decreased	CSF	Aβ1–42 by ac-
cumulation	of	Aβ1–42	in	neuritic	plaques	(Fagan	et	al.,	2006)	resulting	
in	 reduced	drainage	 through	 the	CSF	 (Lautner	 et	al.,	 2014;	 Strozyk,	
Blennow,	White,	&	Launer,	2003),	 and	 in	 increased	 tau	by	neuronal	
death	(Franz	et	al.,	2003;	Itoh	et	al.,	2001)	and	active	secretion	(Chai,	
Dage,	&	Citron,	2012;	Saman	et	al.,	2012).	Phospho-	tau,	unlike	total	
tau, seems to have greater specificity to neurofibrillary tangle pathol-
ogy, and does not drastically increase in some neurodegenerative 
F IGURE  1 Associations	between	global	measures	of	brain	size	and	CSF	biomarkers	(Aβ1–40,	Aβ1–42,	tau,	and	p-	tau181)	in	209	vervets	with	
both	CSF	collection	and	MRI	scan.	Colored	points	denote	the	strength	of	association	–	non-	significant	association	(p	>	.05,	black),	suggestive	
association	(p	<	.05,	yellow),	and	significant	association	(Benjamini-	Hochberg	corrected	p	<	.05,	red)
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diseases	 such	 as	 Creutzfeldt-	Jakob	 disease	 (Itoh	 et	al.,	 2001)	 and	
acute	stroke	(Hesse	et	al.,	2001).	The	relationship	of	CSF	Aβ1–40 with 
AD	has	been	less	clear,	though	CSF	Aβ1–40 has been reported as de-
creased	 in	 CAA	 (Verbeek	 et	al.,	 2009).	 Here,	we	 found	 that	 reduc-
tions	 in	 global	measures	 of	 brain	 size	 (such	 as	 cerebral	volume	 and	
total	brain	surface	area)	were	associated	with	reduced	CSF	Aβ1–40 and 
elevated	CSF	p-	tau181.	Taken	together	with	previous	observations	of	
age-	related	amyloid	plaques	in	the	vervet	(Kalinin	et	al.,	2013;	Lemere	
et	al.,	2004),	the	relationships	with	Aβ1–40	and	p-	tau181 are consistent 
with	 a	 scenario	 of	 age-	related	 accumulation	 of	 amyloid	 plaques	 (in	
parenchyma	and/or	vasculature)	corresponding	to	cerebral	atrophy	in	
the	vervet.	Though	previous	studies	have	found	limited	phospho-	tau	
immunoreactivity and few neurofibrillary tangles in the vervet brain 
(Lemere	et	al.,	2004),	the	fact	that	elevations	in	p-	tau181	levels	in	CSF	
are also correlated with changes in brain morphometry suggest that 
tau pathology may also play a role.
These findings are reminiscent of the observed relationship be-
tween	CSF	biomarkers	and	neuroimaging	measurements	in	aging	and	
neurodegenerative	 disease	 in	 humans.	 Previous	 work	 has	 demon-
strated	 associations	 between	 longitudinal	 changes	 in	Aβ1–42	 and	 p-	
tau231	and	hippocampal	volume	in	AD	and	mild	cognitive	impairment	
(Chou	et	al.,	2009;	De	Leon	et	al.,	2006;	Hampel	et	al.,	2005;	Schuff	
et	al.,	2009)	as	well	as	in	healthy	brain	aging	(Fjell	et	al.,	2010)	in	hu-
mans.	However,	we	 identified	 significant	 associations	of	Aβ1–40, not 
Aβ1–42,	with	age,	gray	matter	thickness,	and	other	measures	of	brain	
size.	In	vervets	(Lemere	et	al.,	2004)	and	in	humans	(Attems,	Jellinger,	
Thal,	&	Van	Nostrand,	2011;	Attems,	Lintner,	&	Jellinger,	2004;	Gravina	
et	al.,	1995),	Aβ1–40	predominates	in	CAA	while	Aβ1–42 predominates 
in	parenchymal	plaques,	and	this	neuropathology	is	reflected	in	differ-
ences	in	the	concentrations	of	these	Aβ	species	in	CSF.	Furthermore,	
the	brain	regions	most	associated	with	decreased	Aβ1–40 in this study 
in	vervet	(predominant	occipital	cortical	involvement,	as	well	as	precu-
neus	and	frontal	cortex)	mirror	the	distribution	of	CAA	and	subsequent	
neurodegeneration	in	humans	(Attems	et	al.,	2011;	Vinters	&	Gilbert,	
1983).	Because	of	 these	converging	 lines	of	evidence,	we	speculate	
that	the	changes	in	Aβ1–40	observed	correlate	with	CAA	pathology,	al-
though	further	study	is	required	to	confirm	this	hypothesis.	In	a	subset	
of this cohort containing 22 vervets ranging from 11 to 26 years of age 
with	neuropathology,	amyloid	plaque	burden	increased	with	age	and	
correlated	inversely	with	CSF	Aβ1–42	levels	(Dr.	Suzanne	Craft,	personal 
communication).	The	lack	of	association	with	CSF	Aβ1–42 with age and 
with	brain	regions	may	reflect	inconsistent	amyloid	plaque	burden	in	
the	aged	vervet,	compared	to	CAA	pathology.
Moreover,	 we	 find	 evidence	 for	 the	 heritability	 of	 CSF	Aβ1–40 
concentrations	 in	 the	 vervet.	 Linkage	 analysis	 identified	 two	 sug-
gestive	 linkage	peaks:	 a	wide	9	cM	peak	on	chromosome	4,	 and	a	
narrow	 6	cM	 peak	 on	 chromosome	 12.	The	 lack	 of	 statistical	 sig-
nificance	 in	 linkage	 analysis	 despite	 the	 moderate	 heritability	 of	
CSF	 Aβ1–40 concentration may suggest a highly polygenic contri-
bution	 to	 the	phenotype.	While	 the	 signal	 did	 not	 reach	 genome-	
wide significance and spanned a wide genomic range, precluding 
identification	of	a	single	causal	gene	or	variant,	our	work	provides	a	
basis for further fine mapping of these regions. Potential candidate 
genes in the region include PTCD2 and MAP1B, at the proximal end 
F IGURE  2 Regional associations of 
cortical	gray	matter	thickness	and	CSF	
Aβ1–40 in the vervet brain; coloration of 
the	region	indicates	suggestive	(p	<	.05,	
orange),	and	significant	association	
(Benjamini-	Hochberg	corrected	p	<	.05,	
red)
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of	the	linkage	peak	and	approximately	330	and	470	kilobases	from	
the	top	associated	marker.	The	pentatricopeptide	repeat	domain	2	
gene, encoded by PTCD2, has been observed to be accumulated in 
AD	 brain	 in	 citrullinated	 form,	 and	 autoantibodies	 against	 PTCD2 
have	been	observed	in	AD	patient	serum	(Acharya	et	al.,	2012).	The	
microtubule-	associated	 protein	 1B,	 encoded	 by	MAP1B, has been 
described	 to	 bind	 tau	 and	 Aβ	 (Gevorkian	 et	al.,	 2008;	 Hasegawa,	
Arai,	 &	 Ihara,	 1990).	 In	 humans,	 genome-	wide	 association	 studies	
have	demonstrated	genetic	loci	that	affect	CSF	biomarkers,	the	most	
robust being the region surrounding the APOE	gene	(Cruchaga	et	al.,	
2013).	The	linkage	analysis	here	may	provide	a	foothold	to	discover	
analogous	loci	for	vervets,	but	further	work	remains	to	validate	and	
pinpoint them.
One observed anomaly was the fact that concentration of total 
tau	was	lower	than	that	for	p-	tau181	in	many	CSF	specimens.	This	was	
unexpected because the phosphorylated species is also reactive to the 
antibodies against total tau, and therefore the concentration of total 
tau should be an upper bound for that of the phosphorylated spe-
cies.	Because	the	calibration	standards	and	controls	were	derived	from	
human	tau,	we	postulated	 that	non-	homology	 in	 the	epitope	 region	
may confound the assay. Indeed, we found an amino acid difference 
in	the	vervet	tau	ortholog	in	the	AT120	epitope	region	that	may	affect	
the	specificity	of	the	antibody.	We	speculate	that	this	lack	of	homol-
ogy accounts for the aberrant total tau levels that were observed and, 
therefore,	the	measurement	of	the	total	tau	using	the	AlzBio3	assay	in	
vervets must be interpreted with caution. The epitope regions for all 
of	the	other	antibodies	used	to	quantify	levels	of	Aβ1–40,	Aβ1–42, and 
p-	tau181 were identical between human and vervet.
Another	 limitation	 of	 the	 study	 is	 the	 fact	 that	 neuroimages	
and	 CSF	 samples	 were	 not	 acquired	 simultaneously;	 the	 inter-
val	between	 imaging	and	CSF	collection	was	variable,	but	 imaging	
was	 performed	 approximately	 5	years	 before	 CSF	 collection	 for	
each sample. Somewhat mitigating the possibility for extensive 
confounding, we had previously demonstrated high heritability of 
neuroimaging	 phenotypes,	 in	 some	 instances	 approaching	 100%;	
therefore,	environmental	influences	are	likely	to	be	low	(Fears	et	al.,	
2009).	We	were	able	to	identify	associations	between	CSF	markers	
and neuroimaging despite this gap, which could introduce further 
variability into the analysis; therefore, the associations we positively 
identified	are	likely	to	reflect	biology.	However,	the	temporal	rela-
tionship	 and	 relative	effect	 sizes	of	 the	CSF	marker-	neuroimaging	
relationship	are	not	known.	 In	other	words,	differences	 in	CSF	Aβ 
and tau concentrations on a population level in vervet can be confi-
dently	correlated	to	aging	and	neurodegeneration	(after	controlling	
for	aging),	but	the	sensitivity	and	degree	of	correlation	remains	un-
clear.	Although	we	cannot	make	a	conclusion	about	the	prognostic	
power	of	CSF	markers,	preliminary	data	suggests	that	CSF	Aβ1–42 is 
a	predictor	of	parenchymal	amyloid	plaques	(Suzanne	Craft,	personal 
communication).	 Interestingly,	 neither	 cerebral	 volume	 or	 p-	tau181 
were associated with age across the wide range of ages in the vervet 
cohort; however, the strongest association was detected between 
p-	tau181 and cerebral volume, suggesting that at least some of the 
associations	were	not	driven	by	dependency	on	age.	Furthermore,	
frank	 cognitive	 deficits	 were	 not	 observed	 or	 ascertained	 in	 the	
vervet	subjects,	and	the	study	design	was	cross-	sectional;	correla-
tion with measures of brain structure and function in future lon-
gitudinal studies may provide additional insight into the extent of 
neurodegeneration.
In	vervets,	CSF	Aβ1–40 decreases with advancing age, correlates 
with	global	and	regional	measures	of	brain	size,	and	has	a	large	her-
itable	 component,	 suggesting	 its	 utility	 as	 a	 biomarker	 of	AD-	 or	
CAA-	like	changes	 in	 this	potentially	valuable	animal	model.	Aβ1–40 
was	most	 closely	 associated	with	 decreases	 in	 gray	matter	 thick-
ness in the frontal lobe and hippocampus, mirroring the regional 
vulnerability	patterns	of	AD.	However,	structural	associations	were	
also observed in the occipital lobe and precuneus, regions that are 
generally	spared	early	in	Alzheimer’s	disease	and	more	reminiscent	
of	the	distribution	of	pathology	in	CAA.	Age-	related	cerebral	atro-
phy	 in	 the	vervet	 likely	 involves	β-	amyloid	pathological	processes,	
and	Aβ1–40	 and	 p-	tau181	 appear	 to	 be	 robust	 biomarkers	 of	 these	
processes, though their sensitivities and correlations to disease pa-
thology	 remain	 important	 open	 questions.	We	 have	 also	 mapped	
suggestive	linkage	peaks	on	vervet	chromosomes	4	and	12	that	cor-
respond	to	CSF	Aβ1–40 concentration and may represent a modifier 
of neurodegeneration. The aged vervet therefore has the potential 
to advance our understanding of the genetics, pathogenesis, and 
treatment of neurodegenerative disease.
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